{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:35:08Z","timestamp":1740105308712,"version":"3.37.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2012R1A1A2041534"],"award-info":[{"award-number":["2012R1A1A2041534"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2011-0015112","2013R1A2A2A01067331"],"award-info":[{"award-number":["2011-0015112","2013R1A2A2A01067331"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.bbrc.2015.05.133","type":"journal-article","created":{"date-parts":[[2015,6,14]],"date-time":"2015-06-14T06:27:52Z","timestamp":1434263272000},"page":"894-899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["RAD001 (everolimus) enhances TRAIL cytotoxicity in human leukemic Jurkat T cells by upregulating DR5"],"prefix":"10.1016","volume":"463","author":[{"given":"Myoung Woo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Eun","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jong","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Woong","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Hoe","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Hee","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2015.05.133_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ng1097-141","article-title":"KILLER\/DR5 is a DNA damage-inducible p53-regulated death receptor gene","volume":"17","author":"Wu","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2015.05.133_bib2","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1038\/onc.2008.298","article-title":"The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2015.05.133_bib3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1084\/jem.186.7.1165","article-title":"Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family","volume":"186","author":"Degli-Esposti","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2015.05.133_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2015.05.133_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/35008667","article-title":"TRAIL receptor-2 signals apoptosis through FADD and caspase-8","volume":"2","author":"Bodmer","year":"2000","journal-title":"Nat. Cell. Biol."},{"key":"10.1016\/j.bbrc.2015.05.133_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1074-7613(00)80212-5","article-title":"Apo2L\/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5","volume":"12","author":"Kischkel","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2015.05.133_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in\u00a0vitro and in\u00a0vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.bbrc.2015.05.133_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrd2924","article-title":"Everolimus","volume":"8","author":"Atkins","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2015.05.133_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ijc.25742","article-title":"Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia\/lymphoma and apoptosis in peripheral T-cell lymphomas","volume":"129","author":"Darwiche","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2015.05.133_bib10","doi-asserted-by":"crossref","first-page":"e102494","DOI":"10.1371\/journal.pone.0102494","article-title":"mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death","volume":"9","author":"Baraz","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2015.05.133_bib11","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","article-title":"Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia","volume":"113","author":"Crazzolara","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2015.05.133_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2010.026997","article-title":"The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia","volume":"96","author":"Saunders","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2015.05.133_bib13","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2015.05.133_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/13543784.2011.541154","article-title":"Current and future directions in mammalian target of rapamycin inhibitors development","volume":"20","author":"Fasolo","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbrc.2015.05.133_bib15","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A\u00a0phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2015.05.133_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2014.116269","article-title":"Activity of everolimus (RAD001) in relapsed and\/or refractory multiple myeloma: a phase I study","volume":"100","author":"G\u00fcnther","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2015.05.133_bib17","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2015.05.133_bib18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/leu.2013.17","article-title":"A\u00a0phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse","volume":"27","author":"Park","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2015.05.133_bib19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrc821","article-title":"Targeting death and decoy receptors of the tumour-necrosis factor superfamily","volume":"2","author":"Ashkenazi","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2015.05.133_bib20","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2015.05.133_bib21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.leu.2404610","article-title":"Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines","volume":"21","author":"Russo","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2015.05.133_bib22","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood-2007-09-114314","article-title":"Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance","volume":"113","author":"Fakler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2015.05.133_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1026131425204","article-title":"Potential mechanisms of leukemia cell resistance to TRAIL-induced apopotosis","volume":"8","author":"Hao","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbrc.2015.05.133_bib24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2015.05.133_bib25","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/cdd.2012.78","article-title":"Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1\/2 pathway in breast epithelial cells","volume":"19","author":"Yerbes","year":"2012","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.bbrc.2015.05.133_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ctrv.2008.11.006","article-title":"TRAIL receptor signalling and modulation: are we on the right TRAIL?","volume":"35","author":"Mahalingam","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbrc.2015.05.133_bib27","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2015.05.133_bib28","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/bjc.2011.456","article-title":"Evaluation of pharmacodynamic biomarkers in a phase 1a trial of dulanermin (rhApo2L\/TRAIL) in patients with advanced tumours","volume":"105","author":"Pan","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2015.05.133_bib29","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2165\/11203770-000000000-00000","article-title":"Everolimus: in advanced renal cell carcinoma","volume":"69","author":"Garnock-Jones","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2015.05.133_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.cdd.4401416","article-title":"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L\/TRAIL-induced apoptosis","volume":"11","author":"Chawla-Sarkar","year":"2004","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.bbrc.2015.05.133_bib31","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-10-2530","article-title":"Targeting aberrant PI3K\/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma","volume":"17","author":"Opel","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2015.05.133_bib32","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1038\/cddis.2014.35","article-title":"Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L)","volume":"5","author":"Min","year":"2014","journal-title":"Cell. Death Dis."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15010323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15010323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T08:58:28Z","timestamp":1655888308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X15010323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0006291X15010323"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.05.133","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAD001 (everolimus) enhances TRAIL cytotoxicity in human leukemic Jurkat T cells by upregulating DR5","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.05.133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}